Kenchappa RS, Dovas A, Argenziano MG, Meyer CT, Stopfer LE, Banu MA, Pereira B, Griffith J, Mohammad A, Talele S et al..  2022.  Activation of STAT3 through combined SRC and EGFR signaling drives resistance to a mitotic kinesin inhibitor in glioblastoma.. Cell Rep. 39(12):110991.

Shi DD, Savani MR, Levitt MM, Wang AC, Endress JE, Bird CE, Buehler J, Stopka SA, Regan MS, Lin Y-F et al..  2022.  De novo pyrimidine synthesis is a targetable vulnerability in IDH mutant glioma.. Cancer Cell. 40(9):939-956.e16.

Pal S, Kaplan JP, Nguyen H, Stopka SA, Savani MR, Regan MS, De Nguyen Q-, Jones KL, Moreau LA, Peng J et al..  2022.  A druggable addiction to de novo pyrimidine biosynthesis in diffuse midline glioma.. Cancer Cell. 40(9):957-972.e10.

Notarangelo G, Spinelli JB, Perez EM, Baker GJ, Kurmi K, Elia I, Stopka SA, Baquer G, Lin J-R, Golby AJ et al..  2022.  Oncometabolite d-2HG alters T cell metabolism to impair CD8 T cell function.. Science. 377(6614):1519-1529.

Abdelmoula WM, Lopez BGimenez-Ca, Randall EC, Kapur T, Sarkaria JN, White FM, Agar JN, Wells WM, Agar NYR.  2021.  Peak learning of mass spectrometry imaging data using artificial neural networks.. Nat Commun. 12(1):5544.

Sarkaria JN, Hu LS, Parney IF, Pafundi DH, Brinkmann DH, Laack NN, Giannini C, Burns TC, Kizilbash SH, Laramy JK et al..  2018.  Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data. Neuro Oncol. 20(2):184-191.

Gampa G, Kim M, Cook-Rostie N, Laramy JK, Sarkaria JN, Paradiso L, DePalatis L, Elmquist WF.  2018.  Brain Distribution of a Novel MEK Inhibitor E6201: Implications in the Treatment of Melanoma Brain Metastases.. Drug Metab Dispos. 46(5):658-666.

Randall EC, Emdal KB, Laramy JK, Kim M, Roos A, Calligaris D, Regan MS, Gupta SK, Mladek AC, Carlson BL et al..  2018.  Integrated mapping of pharmacokinetics and pharmacodynamics in a patient-derived xenograft model of glioblastoma.. Nat Commun. 9(1):4904.

Gampa G, Vaidhyanathan S, Sarkaria JN, Elmquist WF.  2017.  Drug delivery to melanoma brain metastases: Can current challenges lead to new opportunities? Pharmacol Res. 123:10-25.

Laramy JK, Kim M, Gupta SK, Parrish KE, Zhang S, Bakken KK, Carlson BL, Mladek AC, Ma DJ, Sarkaria JN et al..  2017.  Heterogeneous Binding and Central Nervous System Distribution of the Multitargeted Kinase Inhibitor Ponatinib Restrict Orthotopic Efficacy in a Patient-Derived Xenograft Model of Glioblastoma.. J Pharmacol Exp Ther. 363(2):136-147.